Table 9.
Stage 3 or 4 sleep (%) in randomized controlled trials of APAP versus CPAP
| Study PMID |
Baseline AHI (SD) [eligibility] |
Baseline ESS (SD) | Duration (design) | Interventions | Number analyzed | Baseline (SD) | Change (final) |
Net difference or difference |
95% CIa | P | Dropout (%) | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d'Ortho 2000 [32] 11035671 |
58 (6) [≥10] |
12.7 (5.3) | 2 months (XO) |
APAP | 25 | 44 min (36) | 43 | -9 min | nd | NS | 0 | B |
| CPAP | 25 | 44 min (36) | 52 | |||||||||
| Hussain 2004 [20] 15072173 |
47 (36) [> 15] |
11.1 (6.4) | 1 month (XO) |
APAP | 10 | 14 (25) | -4.0 | -8 | -18.32 to 2.32 | nd | 0 | C |
| CPAP | 10 | 14 (25) | 4.0 | |||||||||
| Konermann 1998 [31] 9515848 |
38 (14) [> 20] |
nd | 3 to 6 months (PL) |
APAP | 25 | 13.2 (12.2) |
14 | 7.8 | 1.8 to 13.7b | < 0.01 | 4 | B |
| CPAP | 23 | 11.4 (10.4) |
6.2 | |||||||||
| Meurice 2007 [13] 17638595 |
55 (10) [nd] |
11.8 (4.9) | 6 months (PL) |
APAP (AutoSet) | 15 | 25.5 (14.7) | -4.4 | -5.2 | -13.51 to 3.11 | nd | 15 | B |
| CPAP | 14 | 17.1 (7) |
0.8 | |||||||||
| Nolan 2007 [14] 17326544 |
15 (8) [≥5) |
12.3 (4) | 2 months (XO) |
APAP | 29 | 13.7 (7.8) | 1.3 | 0.3 | -3.29 to 3.89b | 0.87 | 15 | B |
| CPAP | 29 | 13.7 (7.8) | 1.0 | |||||||||
| Randerath 2001 [26] 11254519 |
35 (26) [≥10] |
11.1 (5.1) | 1.5 months (XO) |
APAP | 52 | 14 (11) | 0 | -1 | -3.45 to 1.45 | NS | 12 | B |
| CPAP | 52 | 14 (11) | 1.0 | |||||||||
| Resta 2004 [24] 15679008 |
47 (11) [> 30] |
13.9 (3.2) | 1 month (PL) |
APAP | 10 | 19.8 (10.9) | 14 | 7.3 | -2.35 to 16.95 | nd | 0 | C |
| CPAP | 10 | 22.8 (12.5) |
6.7 | |||||||||
| Sériès 1997 [27] 9341056 |
44 (20) [nd] |
15.5 (4.5) | 0.75 months (PL) |
APAPc | 12 | nd | ndd | - | - | NS | 0 | C |
| CPAP | 12 | nd | nd | |||||||||
| APAPe | 12 | nd | ndd | - | - | NS | ||||||
| CPAP | 12 | nd | nd |
AHI: apnea-hypopnea index (events/hour); APAP: auto-titrating CPAP; CPAP; continuous positive airway pressure; ESS: Epworth Sleepiness Scale; nd: no data; NS: non-significant; PL: parallel design; XO: cross-over design. aEstimated from reported data. bEstimated from reported P value. cEstimated effective pressure. dDirections of changes not reported in the study. eMeasured effective pressure.